Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2024—The new edition of the CAP accreditation program checklists will contain revised requirements for the qualification of laboratory directors, technical and general supervisors, technical and clinical consultants, and moderate- and high-complexity testing personnel.
December 2024—Digital pathology in 2024—what’s the sentiment, the pace, the holdup, the worry? Five people spoke online with CAP TODAY publisher Bob McGonnagle on Oct. 9 about the state of play as the end of the year neared.
December 2024—Payment policies that the CAP championed to protect the value of pathology services have been captured in the 2025 Medicare physician fee schedule published on Nov. 1. The Centers for Medicare and Medicaid Services included in the 2025 fee schedule updated relative value units for three apheresis services and increased nonphysician cost components for key pathology and laboratory labor types. In a separate hospital payment regulation for 2025, the CMS also declined to move forward with surgical pathology tissue exam payment decreases to which the CAP objected.
December 2024—A National Cancer Institute trial known as MyeloMATCH, rolling out now, aims to improve the acute myeloid leukemia survival rate and relies on 72-hour turnaround times for cytogenetics, FISH, flow cytometry, and next-generation sequencing. In MyeloMATCH (Molecular Analysis for Therapy Choice), researchers are hoping to find new treatments for AML and myelodysplastic syndrome by rapidly matching patients with a trial that tests a treatment designed to target the mutations detected in the patient blood and bone marrow samples.
December 2024—Some health systems have sold their clinical laboratory outreach business; others seek to grow theirs. CAP TODAY publisher Bob McGonnagle asked Compass Group members for a quick look at their outreach programs when they met online on Nov. 5. The Compass Group is an organization of not-for-profit IDN system laboratory leaders who collaborate to identify and share best practices and strategies.
December 2024—Case. A 73-year-old male with a clinical history of benign prostatic hypertrophy and pituitary macroadenoma status post-resection presented with lymphocytosis. This incidental lymphocytosis was noted within a preoperative CBC for a prostate procedure. At the time he was asymptomatic; medications included hydrocortisone, testosterone, and levothyroxine. Lymphadenopathy and splenomegaly were absent on physical examination. Complete blood counts showed WBC 25.8 × 109/L, hemoglobin 13.9 g/dL, hematocrit 42 percent, and platelets 134 × 109/L.
November 2024—David Grenache, PhD, D(ABCC), chief scientific officer of TriCore, is breaking no new ground when he considers the maternal serum alpha-fetoprotein test and says, “A screening test is designed to put people into one of two camps.” No scientific advances there. But the reverberations of this particular screening test have landed patients and physicians in complicated situations of late. The obvious divide is to identify increased risk of fetal abnormalities, including open neural tube defects. But the test has historically incorporated a race adjustment for Black patients. And that adjustment—seen as a way to account for reported differences in AFP values between Black and non-Black pregnant persons—in turn has come under more scrutiny recently as physicians question whether the adjustment should continue to be used, or whether it should be dropped, à la the race adjustment for eGFR/renal function. Compared with eGFR, evaluating the race adjustment in maternal serum AFP screening is more in its infancy, Dr. Grenache says.
November 2024—When it comes to what diseases are predicted to circulate and when, expect a respiratory virus season much like last year’s, and the year before that. As for the severity? “That’s anybody’s guess,” says Alesia McKeown, PhD, scientific partner, medical and scientific affairs at Roche Diagnostics, speaking in late September.
November 2024—In the clinical parasitology laboratory at Mayo Clinic, job satisfaction is up and ergonomic strain is down. Work difficulty is down, too, as is the pressure of time.
November 2024—Hemoglobin A1c (HbA1c) is a glycated form of hemoglobin that is increased in individuals with diabetes mellitus. HbA1c concentrations generally reflect plasma glucose levels (and therefore glycemic control) over the past eight to 12 weeks.
